Michael Burgess actually said...
Reauthorizing improved generic and biosimilar user fee programs will lead to timelier approvals and lower drug costs. It's that simple.
Context
Burgess emphasizes the importance of user fee reauthorization for drug cost reduction.
03/01/2017